Ovarian cancer outcomes are less positive for Black and African American persons compared to other communities, but the reasons why are not entirely clear. Anne Mette Buhl, PhD, Director of Science and Clinical Trials, from The Clearity Foundation, recently contributed … Read more
by Cleveland Clinic
Reassessing antibiotic dosage and type could improve survival rates in deadliest gynecologic malignancy, Cleveland Clinic research finds
Newswise — CLEVELAND – Antibiotics routinely used in ovarian cancer care indiscriminately kill gut bacteria, leading to faster cancer progression … Read more
by Mark L. Fuerst
– KELIM score can now be used to look at upfront response, study showed
Tumor primary chemosensitivity testing can help determine if ovarian cancer patients need a boost along with first-line chemotherapy. In the VELIA trial, … Read more
A new type of technology can capture stray ovarian cancer cells from a simple blood test and successfully predict cancer in people who have a lesion or cyst in the pelvic region, according to a new study by a Wilmot … Read more
NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.
For … Read more
by University of Texas M.D. Anderson Cancer Center
Newswise — CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for … Read more
by Caroline Hopkins
CHICAGO – AstraZeneca’s investigational WEE1 inhibitor adavosertib showed potential in biomarker-selected advanced ovarian cancer populations in two studies presented during the American Society of Clinical Oncology’s annual meeting Saturday.
The drug, which AstraZeneca licensed from Merck in … Read more
Biomedical engineer Daniel Heller leads the Cancer Nanomedicine Laboratory at MSK.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed a sensor that can be trained to sniff for cancer, with the help of artificial intelligence.
Although the training … Read more
by Matthew Stenger
In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in … Read more
Blood-based metabolic signatures may predict whether women with ovarian or uterine cancer will respond well to platinum-based chemotherapy, according to a study by researchers in the Department of Gynecology at the Federal University of São Paulo’s Medical School (EPM-UNIFESP) in … Read more
MEDICAL COLLEGE OF WISCONSIN
The study’s findings suggest targeting protein FXR1 to inhibit the progression of the cMYC oncogene, a gene mutation often over-expressed in patients with ovarian cancer
Scientists at the Medical College of Wisconsin (MCW) Cancer Center and … Read more
by Alison Kanski
NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.
Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more
by Julie S. Brokaw
A woman with ovarian cancer describes how blood work numbers play a key role for patients with cancer and often dictate their thoughts and worries.
The number three is a special number. As a former math
RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.
By … Read more
High tumor mutational burden (TMB) was useful for predicting clinical responses to immune checkpoint inhibitors only in a subset of cancer types, according to a study published by McGrail et al in Annals of Oncology.
The findings suggest that … Read more
Residual fixatives from liquid-based Pap tests and cervical swabs contain tumor-specific biomarkers for ovarian cancer, according to an analysis of proteins found in matched biospecimens from a woman with high grade serous ovarian cancer.
The findings suggest … Read more
Receiving a cancer diagnosis can be overwhelming. But the more you know about your specific situation, the better.
By
Every year, more than 21,000 women in the United States are diagnosed with ovarian cancer. In about half of
… Read moreThe study finally paves the way for the use of antibodies different from IgG as immunotherapeutic agents for at least tumors currently resistant to conventional immune checkpoint blockade.
The prognosis of ovarian cancer is poor, with an estimated five-year survival … Read more
By Angus Liu
Many oncology researchers and practitioners scrutinize genetic alterations in cancer, but they either focus on one particular tumor type or one mutation that occurs across tumors. A large-scale study focusing on precision medicine in cancer is now … Read more
